

CURRICULUM VITAE

Z. Nicholas Zakov, MD, FACS
(Zvetan Nikolov Zakov, MD, FACS)

OFFICE ADDRESSES Retina Associates of Cleveland, Inc.
3401 Enterprise Parkway, Suite 300; Cleveland, Ohio 44122
14601 Detroit Avenue, Suite 200; Cleveland, Ohio 44107
15299 Bagley Road, Suite 200; Cleveland, Ohio 44130
5390 Belmont Avenue; Youngstown, Ohio 44505
1 Park West, Suite 150; Akron, Ohio 44320
3919 E. Market Street; Warren, Ohio 44484
9485 Mentor Avenue, Suite 211; Mentor, Ohio 44060
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052

TELEPHONE 216-831-5700

EDUCATION

High School Cleveland Heights High School
Cleveland, OH
1962

College Kenyon College
Gambier, OH
1962–66, BA

Medical School Columbia University
College of Physicians and Surgeons
New York, NY
1966–70, MD

POSTGRADUATE TRAINING

Internship Surgical Internship
Columbia Presbyterian Medical Center
New York, NY
1970–1971

Residency Ophthalmology
Cleveland Clinic Foundation
Cleveland, OH
1973–1976

Fellowships

Retinal & Vitreous Diseases
 Bascom Palmer Eye Institute
 University of Miami
 Miami, FL
 1976–1977

Retinal & Vitreous Diseases
 Clinical & Experimental Pathology
 Howe Laboratory of Ophthalmology
 Massachusetts Eye & Ear Infirmary
 Harvard Medical School
 Boston, MA
 1977–1978

LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio, Colorado, and Pennsylvania

Diplomate, American Board of Ophthalmology 1977

PROFESSIONAL POSITIONS

Retina Associates of Cleveland, Inc. 1990–
 Practice limited to Retinal Diseases and Surgery. Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Hernando Zegarra, MD; Scott D. Pendergast, MD; David G. Miller, MD; Joseph M. Coney, MD; Jerome P. Schartman, MD

Visiting Student 1970
 Institute of Ophthalmology and Moorfields Eye Hospital,
 London, England

General Medical Officer 1971–73
 U.S. Public Health Service, Indian Health Service
 Belcourt, ND
 Rank at retirement: Lieutenant Commander

Diplomate 1973
 Lancaster Basic Course in Ophthalmology

Associate Staff Member 1976–78
 Department of Ophthalmology
 Cleveland Clinic Foundation
 Cleveland, OH

Lecturer	1977–82
Ophthalmic Pathology Section Harvard Basic Science Course in Ophthalmology	
Consultant	1978
National Institute for Occupational Safety and Health Epidemiologic Field Study of the Incidence of Uveal Melanoma in a Population of Chemical Workers	
Lecturer	1980–84
Ophthalmic Pathology Section Case Western Reserve University Basic Science Course in Ophthalmology	
Staff Member	1978–1990
Retinal and Vitreous Section, Department of Ophthalmology Cleveland Clinic Foundation Cleveland, OH	
Head, Section of Retinal & Vitreous Disease	1986–1990
Department of Ophthalmology Cleveland Clinic Foundation Cleveland, OH	
Corporate Consultant (unpaid)	2006–2010
Synergetics, Inc. O'Fallon, MO	
Fellow of the Royal Society of Medicine	2010–

ACADEMIC APPOINTMENTS

Clinical Professor of Ophthalmology, 2007–
Associate Clinical Professor of Ophthalmology, 1997–2007
Assistant Clinical Professor of Ophthalmology, 1990–1997
Case Western Reserve University School of Medicine
Cleveland, Ohio

PROFESSIONAL SOCIETIES AND COMMITTEES

Retina Society
Program Co-Chairman, 1985
Credentials Committee, 1986–89
Chairman of Committee, 1988–89
By-laws Committee Chairman, 2002–2010

- American Society of Retina Specialists (formerly the Vitreous Society)
Program Co-Chairman, 1985, 1986
Board of Directors, 1985–2008
President, 1987–88
By-laws Committee Chairman, 1991–96
Awards Committee Founder and Chairman, 1996–2006
Emeritus Director, 2001–2008
Practice Management Committee Founder and Chairman, 1999–2002
Liaison to the American Retina Foundation, 2002–2006
Representative to the American Academy of Ophthalmology Council, 2006–2012
- American Academy of Ophthalmology Council
Co-chair, Great Lakes section, 2007–2009
- American Board of Ophthalmology
Associate Examiner, 1986–2010
- Cleveland Ophthalmological Society
President, 1992–93
President-Elect, 1991–92
Chairman, Education Program Committee, 1991–92
Executive Committee, 1991–94
Peer Review Committee, 1991–92
- American Society of Ocular Trauma (formerly the US Eye Injury Registry)
Founding President, 2002
Emeritus Director, 2002–2008
Board of Directors, 2002–2008
- American Eye Study Club
Member, 1982–1992
Emeritus Member, 1992–
Charitable Foundation Committee, 2002–2006
- Cleveland Clinic
Program Co-Chairman, Dedicatory Meeting of new Department of Ophthalmology, 1986
- Hillcrest Hospital
Head, Section of Retinal/Vitreous Diseases and Surgery, 1990–2008
Diabetes Education Committee, 1991–1999
- University Hospitals of Cleveland, Department of Ophthalmology and Visual Sciences
Member, Appointments, Promotions, and Tenure Committee, 1998–1999, 2007–2009
- Case Western Reserve University School of Medicine
Member, Advisory Board for Macular Degeneration Research, 2008–
- Cleveland Eye Bank
35th Anniversary Campaign Committee
- Ohio Eye Injury Registry
Scientific Co-Director, 1994–1998
- United States Eye Injury Registry
Board of Directors, 1994–2008
President-Elect, 1996–1998
President, 1998–2003
By-laws Committee, 1997–2008

Executive Committee, 1996–2002
 Nominating Committee, 1996–2002
 South East European Ophthalmological Society (formerly the Balkan Ophthalmological Society)
 Founding Member, 1998
 By-laws Committee, 1998–2002
 International Society of Ocular Trauma
 By-laws Committee, 2000–2008
 Organizing Committee, 2003 Meeting, Sopron, Hungary
 International Scientific Committee, International Symposium on Ocular Trauma, 2006, Rome, Italy
 Eye Fly Club
 Naming Co-Chairman
 Visionary Practitioner Recognition Award Program, Pfizer Ophthalmics
 Co-Chairman, 2003–2004
 Mediterranean Retina Meeting, 2004–
 Co-Founder and Co-Director with Dr. Murat Oncel
 Ayhan Sahenk Award for Vitreoretinal Excellence
 Creator, in conjunction with the Sahenk Family
 First awarded in 2004 at the Mediterranean Retina Meeting
American Journal of Ophthalmology
 Scientific Reviewer
American Society of Retina Specialists (formerly the Vitreous Society) Online Journal
 Editorial Board, 1998–2008
Cleveland Clinic Journal of Medicine, Editorial Committee
 Book Review Editor, 1983–89
Ocular Surgery News
 Book Review Editor, 1989–2004
Ophthalmic Lasers and Surgery
 Scientific Reviewer
Ophthalmology
 Scientific Reviewer
Retina-Vitreus (Turkish Retinal Journal)
 Editorial Board, 1993–2004

HONORS AND AWARDS

Lubrizol Corporation Chemistry Prize	1962
Phi Beta Kappa	1965
Summa cum laude, highest honors in biology	1966
Robert Bowen Brown, Jr. Prize in biology	1966
Alvin Behrens Memorial Prize in Ophthalmology	1970
Heed Ophthalmic Foundation Fellowship	1976–77

American Board of Ophthalmology-Certificate of Appreciation for Participation as an Associate Examiner	1986–91
Vitreous Society (American Society of Retinal Specialists) Leadership Award	1987
Excellence in Teaching Award, Mt. Sinai Medical Center	1991
Vitreous Society (American Society of Retinal Specialists) Honor Award	1998
Honor Award, American Academy of Ophthalmology	1998
Public Service Award, Ohio Ophthalmological Society,	1998, 1999
Senior Honor Award, Vitreous Society (American Society of Retinal Specialists)	2001
Leadership Award, American Society of Ocular Trauma	2002
Best Doctors in America	1996–2011
Best Doctors in Cleveland, <i>Cleveland Magazine</i>	1998–2011
Ambassador of Goodwill of Israel, Israel Ministry of Tourism	2003
Honorary member of the Union of Bulgarian Ophthalmologists	2004
Honorary citizen of the city of Dubrovnik, Croatia	2005
Nikos Kazantzakis Medal of the University of Crete, Greece On the occasion of the 10 th Aegean Retina Meeting	2007
Appreciation Award for Dedication and Service Council of the American Academy of Ophthalmology	2008
American Retina Foundation Award in recognition of extensive work with the Foundation and of outstanding contributions as a founding member and as past president	2009
Mediterranean Retina Board Friendship Award for longstanding contribution and collaboration Turkish Ophthalmology Society Fourth Mediterranean Retina Meeting	2010

MEMBERSHIPS

American Academy of Ophthalmology
 American College of Surgeons
 American Eye Study Club
 American Society of Ocular Trauma
 American Society of Retinal Specialists (formerly the Vitreous Society)
 U.S. Eye Injury Registry
 Retina Society
 Macula Society
 Aspen Retinal Detachment Society
 Ohio Ophthalmological Society
 Academy of Medicine of Cleveland
 Cleveland Ophthalmological Society
 Turkish American Ophthalmological Society
 Aegean Retina Meeting Group
 International Society of Ocular Trauma
 International Society of Ophthalmic Ultrasound

Schepens International Society
Macular Degeneration International
Pan-American Association of Ophthalmology
South East European Ophthalmological Society
Eye Fly Club
European Vitreoretinal Society

HOSPITAL AFFILIATIONS

University Hospitals of Cleveland
Hillcrest Hospital
Lakewood Hospital
University Hospitals Health System Geauga Regional Hospital (Chardon, OH)
University of Pittsburgh Medical Center (UPMC)

RESEARCH ACTIVITIES

NIH-funded Grants

Collaborative Ocular Melanoma Study

Co-investigator, Cleveland Clinic Center, 1987–2003

Principal Investigator, Retina Associates of Cleveland Center, 1997–2003

Choroidal Neovascularization Prevention Trial – Pilot Study

Co-investigator, 1995–2001

Complications of Age-related Macular Degeneration Prevention Trial

Co-investigator, 1998–

Diabetic Retinopathy Clinical Research Network Protocol #1A. A pilot study of laser photocoagulation for diabetic macular edema.

Co-investigator, 2003–

*Standard Care vs. **C**orticosteroid for **R**etinal Vein Occlusion (**SCORE**) Study*

Co-investigator, 2004–2009

Age-Related Eye Disease Study 2

Co-investigator, 2006–

Other National Clinical Trials

Choroidal indeterminate melanocytic lesions prompt vs deferred treatment—a multi center randomized study

Principal Investigator, 2008–

Hydrokinetic retinal manipulation using the liquid and viscous fluorocarbon perfluorophenanthrene

Principal Investigator, 1993–94

Oculon Study. Evaluation of the efficacy of OC-2 in the inhibition of cataract formation associated with vitrectomy surgery

Co-investigator, 1993–94

Alfa-interferon treatment of choroidal neovascularization

Co-investigator, 1993–96

Protocol SO14297 Interferon Alfa-2a

Co-investigator, 1994–96

Perfluron™ (perfluoro-n-octane) for use in the treatment of complicated retinal detachment

Co-investigator, 1995–1996

Vitrace™ for Vitreous Hemorrhage Study

Co-investigator, 1998–1999

Age-related Macular Degeneration / Thalidomide Study

Co-investigator, 1995–2000

An evaluation of safety and duration of efficacy of anecortave acetate sterile suspension (30 mg, 15 mg or 3 mg) versus placebo following a single sub-Tenon's injection for the inhibition of neovascularization in patients with age-related macular degeneration

Co-investigator, 1998–2001

Open-label, multicenter, safety study of the treatment of predominantly classic choroidal neovascularization secondary to age-related macular degeneration using photodynamic therapy with verteporfin for injection

Co-investigator, 1999–2000

Evaluation of efficacy and safety of a sub-Tenon's injection of anecortave acetate sterile suspension versus placebo in patients with exudative age-related macular degeneration (AMD) following treatment with photodynamic therapy (PDT) using Visudyne™

Co-investigator, 2000–2001

Protein Kinase C β Inhibitor – Diabetic Macular Edema Study and Diabetic Retinopathy Studies

Co-investigator, 1998–2002

Oculex Study: A Phase 2 randomized, multicenter, dose-ranging, controlled, parallel-group trial to assess the safety and effectiveness of dexamethasone posterior segment drug delivery system (DEX PS DDS[®]) in the treatment of persistent macular edema

Co-investigator, 2001–2003

Phase II/III randomized, double-masked, controlled, dose-ranging, multicenter comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (anti-VEGF pegylated aptamer) given every 6 weeks for 54 weeks in patients with AMD

Co-investigator, 2001–2006

Protein Kinase C β Inhibitor – Diabetic Retinopathy Study 2.

Co-investigator, 2001–2006

Fluocinolone Acetonide in Diabetic Macular Edema (FAME 4) Study. A multicenter, randomized, masked, controlled study to evaluate the safety and efficacy of Retisert™, an intravitreal fluocinolone acetonide implant, in the treatment of patients with diabetic macular edema

Co-investigator, 2001–2007

Intravitreal Steroid Injection Studies (ISIS)

Co-investigator, 2002–2006

The Implantable Miniature Telescope (IMT™) in patients with central vision impairment associated with age-related macular degeneration or Stargardt's macular dystrophy

Co-investigator, 2003–2005

A Phase III, multicenter, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFabv2 (ranibizumab) compared with verteporfin (Visudyne) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration (ANCHOR)

Co-investigator, 2003–2006

A randomized, single-masked, multicenter, Phase 2 evaluation of the effect of photodynamic therapy using verteporfin (Visudyne® Therapy) in combination with intravitreal injection of either 0 mg, 1 mg, or 4 mg of triamcinolone acetonide in occult subfoveal and minimally classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD): Visudyne with Intravitreal Triamcinolone Acetonide (VisTA) Trial

Co-investigator, 2004–2006

Eyeteq 1011B: A Phase II randomized, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreal injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to central retinal vein occlusion)

Co-investigator, 2004–2006

Protein Kinase C β Inhibitor Study B7A-MC-MBDL. Reduction in the occurrence of center-threatening diabetic macular edema

Co-investigator, 2004–2010

Anecortave Acetate Risk-Reduction Trial (AART)

Co-investigator, 2004–2008

A randomized, double-masked, placebo controlled, parallel group, multi-center, dose-ranging study of denufosol tetrasodium (INS37217) intravitreal injection in subjects with rhegmatogenous retinal detachment

Co-investigator, 2004–2006

An open label study for the evaluation of tolerability of four dose levels of Cand5 administered by single intravitreal injection in patients with wet age-related macular degeneration

Co-investigator, 2005–2007

A Phase II, dose ranging, open-labeled, multi-center study to evaluate the safety and efficacy of combretastatin A4 phosphate for treating subfoveal choroidal neovascularization in subjects with pathologic myopia

Co-investigator, 2005–2006

Phase IV study of daily dosing (vs. previous “on demand”) of Cialis vs. Viagra vs. placebo and its effect on visual functioning in healthy males or those with mild erectile dysfunction

Co-investigator, 2005–2006

Phase 3 assessment of the safety and efficacy of two doses of dexamethasone vs. sham treatment with the dexamethasone posterior segment drug delivery system applicator in patients with macular edema following central retinal vein occlusion or branch retinal vein occlusion.

Co-investigator, 2005–2007

Eyetech 1012: A Phase 4, randomized, active controlled, double masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreal injections of Macugen® given every 6 weeks for 102 weeks plus sham photodynamic therapy (PDT), to Macugen plus PDT® with Visudyne in subjects with predominantly classic subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)

Co-investigator, 2005–2007

Cand5 Anti-VEGF RNAi Evaluation (CARE): Dose comparison of Cand5 for subfoveal choroidal neovascularization associated with wet age-related macular degeneration

Co-investigator, 2005–2007

Veritas: A 24-month randomized, double-masked, sham controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin (Visudyne®) plus two different dose regimens of intravitreal triamcinolone acetonide (1 mg and 4 mg) versus Visudyne® plus intravitreal pegaptanib (Macugen®) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, 2005–2006

Natural history study of macular telangiectasia (MacTel)

Co-investigator, 2005–

RNAi Assessment of Cand5 in Diabetic Macular Edema (RACE)

Co-investigator, 2005–2007

A 3-year, Phase III, multicenter, masked, randomized, sham-controlled trial to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with diabetic macular edema

Co-investigator, 2005–2006

A 6-month, Phase III, multicenter, masked, randomized, sham-controlled trial (with 6-month open-label extension) to assess the safety and efficacy of 700 µg and 350 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in the treatment of patients with macular edema following branch retinal vein occlusion or central retinal vein occlusion

Co-investigator, 2005–2007

The effect of ruboxistaurin on clinically significant macular edema in patients with diabetes mellitus, as assessed by optical coherence tomography

Co-investigator, 2005–

Protocol FVF3426g (HORIZON): An open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age related macular degeneration (AMD) who have completed the treatment phase of a Genentech-sponsored ranibizumab study

Co-investigator, 2006–2007

A Phase IIIb, multicenter study to evaluate the safety and tolerability of ranibizumab in naïve and previously treated subjects with choroidal neovascularization secondary to age-related macular degeneration (SAILOR)

Co-investigator, 2006–2007

Macugen (pegaptanib sodium) for angioid streaks complicated by choroidal neovascular membrane

Co-investigator, 2006–2010

Macugen (pegaptanib sodium) for pathological myopia complicated by subfoveal choroidal neovascularization

Co-investigator, 2006–2010

A multi-center, double-masked, randomized, vehicle-controlled, parallel group evaluation of the safety and efficacy of OT-551 ophthalmic solution to prevent formation or delay progression of nuclear cataract formation in post-vitrectomy patients

Co-investigator, 2006–2007

Study of the efficacy and safety of intravitreal injection of Macugen for neovascular lesions of AMD with recent onset

Co-investigator, 2006–

Eyetech 1023: Phase IV, open label, multicenter trial of maintenance intravitreal injections of Macugen® (pegaptanib sodium) given every 6 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement

Co-investigator, 2006

Sirion randomized, double-masked, dose-ranging, multi-center, Phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration

Co-investigator, 2006–2007

SIRIUS: A 2-year, multicenter, randomized, controlled, masked, dose-finding trial to assess the safety and efficacy of multiple intravitreal injections of AGN 211745 in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, 2006–2008

Age-related Macular Degeneration: Detection of Onset of new Choroidal neovascularization (AMD DOC): Comparison of PHP (Preferential Hyperacuity Perimetry) with supervised Amsler grid in detecting neovascular AMD in eyes at high risk for CNV

Co-investigator, 2007–2009

Denali: a 24-month randomized, double-masked, controlled, multicenter, phase IIIB study assessing safety and efficacy of verteporfin (Visudyne® photodynamic therapy administered in conjunction with ranibizumab (Lucentis®) versus ranibizumab (Lucentis®) monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Co-investigator, 2007

OMEGA: a randomized, double-masked, dose-ranging, multi-center, phase II study comparing the safety and efficacy of OT-551 with placebo to treat geographic atrophy associated with age-related macular degeneration

Co-investigator, 2007–2009

COBALT: COmbining Bevasiranib And Lucentis Therapy. A phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis®, compared with Lucentis® monotherapy every 4 weeks in patients with exudative age-related macular degeneration (AMD)

Co-investigator, 2007–2008

Indocyanine green (ICG) angiographic evaluation of ranibizumab (Lucentis®) treatment of pigment epithelial detachment (PED) associated with age-related macular degeneration (AMD)

Co-investigator, 2007–2010

A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE)

Co-investigator, 2007–

A masked, multicenter, randomized, controlled trial to assess the safety and efficacy of 700 µg dexamethasone posterior segment drug delivery system (DEX PS DDS) applicator system in combination with laser photocoagulation compared with laser photocoagulation alone in the treatment of subjects with diffuse diabetic macular edema

Co-investigator, 2007–2009

A multicenter, randomized, placebo-controlled, double-masked, parallel group, dose-ranging clinical trial of intravitreal microplasmin in patients undergoing surgical vitrectomy: The MIVI III (Microplasmin For Vitreous Injection III) Trial

Co-investigator, 2007–2008

Phase 1, single ascending dose trial to establish the safety, tolerability, and pharmacokinetic profile of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) monotherapy and of E10030 given in combination with Lucentis 0.3mg/eye in subjects with neovascular AMD (Ophthotech 1000)

Co-investigator, 2007–

Phase 1, single ascending dose and parallel group trial to establish the safety, tolerability, and pharmacokinetic profile of multiple intravitreal injections of Volociximab ($\alpha 5\beta 1$ integrin antagonist) as monotherapy or given in combination with Lucentis 0.5mg/eye in subjects with neovascular AMD (Ophthotech 3000)

Co-investigator, 2008–

Phase 2, randomized, double-masked, placebo-controlled, dose-ranging clinical study to assess the safety and efficacy of subconjunctival injections of sirolimus in patients with diabetic macular edema secondary to diabetic retinopathy

Co-investigator, 2008–2010

Natural History of Geographic Atrophy Progression (GAP) Study (Alcon)

Co-investigator, 2008–2009

Geographic Atrophy Treatment Evaluation (GATE) Study (Alcon)

Co-investigator, 2009–

Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion

Co-investigator, 2009–

Phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration

Co-investigator, 2010–

Phase 1 multicenter open-label safety and tolerability clinical trial of ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia Type 2 (Mactel)

Co-investigator, 2011 –

SCIENTIFIC PRESENTATIONS

Over 300 lectures, posters, and presentations 1974–

VISITING PROFESSOR AND LECTURER

Erie Ophthalmological Society	1979
Youngstown Ophthalmology Group	1980
Caylor-Nickel Clinic	
Bluffton, Indiana	1980
Venezuelan Ophthalmology Society	1982
Peruvian Ophthalmology Society	1984
West Virginia University, Department of Ophthalmology	1989
Morgantown, West Virginia	
Aegean University	
Izmir, Turkey	1989
University of Istanbul, Cerrahpasa Medical School	1989
Istanbul, Turkey	1989
St. Francis Medical Center	
Pittsburgh, Pennsylvania	1989
Buffalo Ophthalmological Society	1989
University of Buffalo, Buffalo, NY	
Turkish Ophthalmological Society Annual Meeting	1990
Ankara, Turkey	1990
University of South Florida	
Tampa, Florida	1992
University of Akron	
Akron, Ohio	1993
Youngstown Ophthalmology Group	1993
Gazi University	
Ankara, Turkey	1993
V Tubingen Detachment Course	
Plovdiv, Bulgaria	1993
University of Istanbul, Cerrahpasa Medical School	1998
Istanbul, Turkey	
Thirty-first Panhellenic Ophthalmological Congress	1998
Halkidiki, Greece	
Harkness Eye Institute, Department of Ophthalmology	1998
Columbia University College of Physicians & Surgeons	
New York, New York	
Second Congress of the Union of Bulgarian Ophthalmologists	1999
Borovets, Bulgaria	
Keynote Speaker	
XIII th European Congress of Ophthalmology	2001
Istanbul, Turkey	

Thirty-fifth Panhellenic Ophthalmological Congress Halkidiki, Greece	2002
Goldschleger Eye Institute Annual Meeting Tel Aviv, Israel	2003
Vitreoretinal Symposium I Lodz, Poland	2003
The 6th International Advanced Vitreo Retinal Surgery Course (6th IAVRSC) and Silver Jubilee Celebrations of Sankara Nethralaya Chennai, India Keynote Speaker	2003
Seventh Congress of the Union of Bulgarian Ophthalmologists Plovdiv, Bulgaria Keynote Speaker	2004
Mediterranean Retina Meeting I Antalya, Turkey Organizer	2004
XIII Afro-Asian Council of Ophthalmology Istanbul, Turkey	2004
Vitreoretinal Symposium II Lodz, Poland	2005
Mediterranean Retina Meeting II Antalya, Turkey Organizer	2006
International Retina Congress Tenth Anniversary of the Retina Institute of Karnataka Bangalore, India Chief Discussant	2006
University of Ljubljana Ljubljana, Slovenia	2007
Ravenna International Courses in Ophthalmology Ravenna, Italy	2007
Mediterranean Retina Meeting III Antalya, Turkey Organizer	2008
Vitreoretinal Symposium IV Lodz, Poland	2010
Mediterranean Retina Meeting IV Antalya, Turkey Organizer	2010
Croatian Ophthalmology Congress Dubrovnik, Croatia	2010

MISCELLANEOUS CHARITIES, ACTIVITIES, AND BOARDS

Alumni activities, Kenyon College

Extern Sponsor Program, 1978–1995

25th, 30th, and 35th Reunions CommitteeGift Chair, 35th Reunion

Class of '66 Special Gift Co-Chairman

Alumni Association Distinguished Service Award, 2006

Tourette Syndrome Association of Ohio, Inc.

Board of Trustees, 1986–89

Vice President, 1987–88

The North Hanna Foundation Educational Fund

Board of Trustees, 1995–

Zakov Family Scholarship

Established 1997 at Ferris State University, Big Rapids, Michigan

Zakov Family Scholarship

Established 2002 at Kenyon College, Gambier, Ohio

American Eye Study Club Foundation

Board of Trustees, 2003–

American Retina Foundation (formerly the Vitreous Society Foundation)

Board of Trustees, 1998–

Ad Hoc Committee, 1999–

Vice President, 2000–2006

Founding Donor, 2005

President, 2006–2009

Docent, Body Worlds II

Great Lakes Science Center, Cleveland, Ohio, 2005

Philosophical Club of Cleveland

Member, 2007

Treasurer, 2009–2010

Secretary, 2010–2011

Travelers' Century Club

Member, 2008–

The Union Club

Member, 2008–

The Club at Hillbrook

Member, 2008–

NCI Book Club

Member, 2010–

Rowfant Club

Member, 2011–

PUBLICATIONS

Articles and Chapters

1. Cohen DN, Zakov ZN. The diagnosis of Adie's pupil using 0.0625% pilocarpine solution. *Am J Ophthalmol* 1975;79:883-884.
2. Cohen DN, Zakov ZN, Salanga VD, Dohn DF. Raeder's paratrigeminal syndrome. A new etiology. *Am J Ophthalmol* 1975;79:1044-1049.
3. Gutman FA, Zegarra H, Zakov ZN. Temporal retinal branch vein occlusion. Correlation of fluorescein angiography and visual prognosis. In Cant JS (ed.). *Vision and Circulation*, Third William MacKenzie Memorial Symposium. St. Louis: CV Mosby Co., 1976.
4. Gutman FA, Zakov ZN, Zegarra H. Retinal branch vein occlusion. *Persp Ophthalmol* 1977;1:2-8.
5. Zakov ZN, Berlin AJ, Machemer CJ. Blepharoptosis as a complication of soft lens wear. *Contact and Intraocular Lens Med J* 1977;3:22-23.
6. Zakov ZN, Lewis ML. Iris fluorescein angiography in diabetic vitrectomy patients. *Albrecht von Graefes Arch Klin Ophthalmol* 1978;206:17-24.
7. Gunderson T, Smith TR, Zakov ZN, Albert DM. Choroidal melanocytic tumor observed for 41 years before enucleation. *Arch Ophthalmol* 1978;96:2089-2092.
8. Zakov ZN, Smith TR, Albert DM. False-positive 32p uptake test. *Arch Ophthalmol* 1978;96:2240-2243.
9. Stowe CG, Zakov ZN, Albert DM. Central retinal vascular occlusion associated with oral contraceptives. *Am J Ophthalmol* 1978;86:798-801.
10. Zakov ZN, Dohlman CH, Perry HD, Albert DM. Corneal donor material selection. *Am J Ophthalmol* 1978;86:605-610.
11. Zakov ZN, Rich L, Zegarra H, Gutman FA. Differential diagnosis of preretinal neovascularization. *Persp Ophthalmol* 1978;2:223-231.
12. Albert DM, Zakov ZN, Smith TR. Late diagnosis of choroidal malignant melanoma in eyes with clear media and low visual acuity. *Ophthalmology* 1979;86:1037-1047.
13. Weichselbaum R, Zakov ZN, Albert DM, Friedman AM, Nove J, Little JB. New findings in the chromosome 13 long arm deletion syndrome and retinoblastoma. *Ophthalmology* 1979;86:1191-1198.

14. Kim E, Zakov ZN, Albert DM, Smith TR, Craft JL. Intraocular reticulum cell sarcoma. A case report and literature review. *Albrecht von Graefes Arch Klin Ophthalmol* 1979;208:167-178.
15. The Miami Study Group. Cystoid macular edema in aphakic and pseudophakic patients. *Am J Ophthalmol* 1979;88:44-48.
16. Stowe GC 3rd, Zakov ZN, Albert DM, Smith TR, Sang DN, Craft JL. Vascular basophilia in ocular and orbital tumors. *Invest Ophthalmol Vis Sci* 1979;18:1068-1075.
17. Albert DM, Lesser RL, Cykier RC, Zakov ZN. Orbitofacial mucormycosis occurring with deposition of calcium salts of fatty acids. *Br J Ophthalmol* 1979;63:699-703.
18. Wong S, Zakov ZN, Albert DM. Scleral and choroidal ossification in a patient with pseudohypoparathyroidism. *Br J Ophthalmol* 1979;63:177-180.
19. Gragoudas ES, Zakov ZN, Albert DM, Constable IJ. Long-term observations in proton-irradiated monkey eyes. *Arch Ophthalmol* 1979;97:2184-2191.
20. Zakov ZN, Lewis ML. The vitreous. *Year Book of Ophthalmology* 1979, 223-225.
21. Albert DM, Puliafito CA, Fulton AB, Robinson NL, Zakov ZN, Dryja TP, Smith AB, Egant E, Leffingwell SS. Increased incidence of choroidal malignant melanoma occurring in a single population of chemical workers. *Am J Ophthalmol* 1980;89:323-337.
22. Fulton AB, Craft JL, Zakov ZN, Howard RO, Albert DM. Retinal anomalies in Trisomy 18. *Graefes Arch Ophthalmol* 1980;213:195-205.
23. Zakov ZN, Cook, S.A., Albert DM, Weichselbaum RR. False-positive phosphorus 32 uptake tests in the diagnosis of ocular melanomas. *Int Ophthalmol Clin* 1980;2:117-121.
24. Dryja TP, Zakov ZN, Albert DM. Adenocarcinoma arising from the epithelium of the iris and ciliary body. *Int Ophthalmol Clin* 1980;2:177-190.
25. Albert DM, Robinson NL, Fulton AB, Zakov ZN, Dryja TP, Puliafito CA, Smith AB, Egant E. Epidemiological investigation of increased incidence of choroidal melanoma. *Int Ophthalmol Clin* 1980;2:71-92.
26. Lubin JR, Grove A Jr, Zakov ZN, Albert DM. Hepatoma metastatic to the orbit. *Am J Ophthalmol* 1980;89:268-273.
27. Bienfang DC, Zakov ZN, Albert DM. Severe electrical burn of the eye. *Albrecht von Graefes Arch Klin Ophthalmol* 1980;214:147-153.

28. Sakamoto DK, Zegarra H, Gutman FA, Zakov ZN. Silicone sponge implant in combination with episcleral implant for retinal detachment surgery. *Ophthalmic Surg* 1980;11:217-219.
29. Gutman FA, Zegarra H, Rauer A, Zakov ZN. Photocoagulation in retinal branch vein occlusion. *Trans Am Ophthalmol Soc* 1980;78:156-166..
30. Lowder CY, Tomsak RL, Zakov ZN, Hahn J. Visual loss from pituitary tumor masked by optic nerve drusen. *Neurosurgery* 1981;8:473-476.
31. Wilhelm JL, Zakov ZN, Weinstein M., Zegarra H, Berlin LA, Gutman FA. Localization of suspected intraocular foreign bodies with a modified Delta 2020 scanner. *Ophthalmic Surg* 1981;12:633-641.
32. Wilhelm JL, Zakov ZN, Hoeltge GA. Erythropheresis in treating retinal detachments secondary to sickle cell retinopathy. *Am J Ophthalmol* 1981;92:582-583.
33. Dreyer WB Jr, Zegarra H, Zakov ZN, Gutman FA. Sympathetic ophthalmia. A case report. *Am J Ophthalmol* 1981;93:816-823.
34. Brockhurst RJ, Albert DM, Zakov ZN. Pathologic findings in familial exudative vitreoretinopathy. *Arch Ophthalmol* 1981;99:2143-2146.
35. Gutman FA, Zegarra H, Rauer A, Zakov ZN. Photocoagulation in retinal branch vein occlusion. *Ann Ophthalmol* 1981;13:1359-1363.
36. Lowder CY, Gutman FA, Zegarra H, Zakov ZN, Lowder JN. Macular and paramacular detachment of the neurosensory retina associated with systemic diseases. *Trans Am Ophthalmol Soc* 1981;Vol. LXXIX.
37. Wilhelm JL, Zakov ZN. Choroidal malignant melanoma with liver metastasis prior to enucleation. *Ann Ophthalmol* 1982;14:789-796.
38. Cassen JH, Meisler DM, Zakov ZN, Langston RHS. Donor material for corneal grafting. *Am J Ophthalmol* 1983;95:711-712.
39. Aaby AA, Price RL, Zakov ZN. Spontaneously regressing retinoblastoma, retinoma, or retinoblastoma Group O. *Am J Ophthalmol* 1983;96:315-320.
40. Zegarra H, Gutman FA, Zakov ZN, Carim M. Partial occlusion of the central retinal vein. *Am J Ophthalmol* 1983;96:330-337.
41. Zakov ZN, Berlin LA, Gutman FA. Ultrasonographic mapping of vitreoretinal abnormalities. *Am J Ophthalmol* 1983;96:622-631.
42. Rockwood EJ, Zakov ZN, Bay JW. Combined malignant lymphoma of the eye and central nervous system (reticulum cell sarcoma). A report of three cases. *J Neurosurg* 1984;61:369-374.

43. Rockwood EJ, Meyers SM, Meisler DM, Zakov ZN, Langston RHS. Treatment of selected cases of pupillary block with YAG laser iridotomies. (Letter to the Editor). *Ophthalmic Surg* 1984;15:968.
44. Ludwig IH, Zegarra H, Zakov ZN. The acute retinal necrosis syndrome. Possible herpes simplex retinitis. *Ophthalmology* 1984;51:1659.
45. Effron L, Zakov ZN, Tomsak RL. Neovascular glaucoma as a complication of Wyburn-Mason syndrome. *J Clin Neuro-Ophthalmol* 1985;5:95-98.
46. Preslan M, Beauchamp GR, Zakov ZN. Congenital glaucoma and retinal dysplasia. *J Ped Ophthalmol Strabismus* 1985;22:166.
47. Stern RM, Zakov ZN, Zegarra H, Gutman FA. Multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. *Am J Ophthalmol* 1985;100:560-569.
48. Fung WD, Zakov ZN, et al. Vitrectomy for chronic aphakic cystoid macular edema. Results of a national, collaborative, prospective, randomized investigation. *Ophthalmology* 1985;92:1102-1111.
49. Bale AE, Ludwig IH, Effron LA, Zakov ZN. Linkage between the genes for Wolfram Syndrome and Brachydactyly E. (Letter to the Editor). *Am J Med Genetics* 1985;20:733-734.
50. Beauchamp GR, Meisler DM, Greaves A, Zakov ZN, McMahon JT. Corneal melanocytes in aniridia. *Arch Ophthalmol* 1986;104:799-800.
51. Rabon RJ, Zakov ZN, Meyers SM, Wilbourn AJ. Ulnar nerve mononeuropathies after face-down positioning. *Am J Ophthalmol* 1986;102:125.
52. Stern RM, Zakov ZN, Meisler DM, Hall GS, Martin, A. Endogenous Pseudoallescheria boydii endophthalmitis. *Cleve Clin Quarterly* 1986; 53:197-203.
53. Cole EL, Zakov ZN, Meisler DM. Cutaneous malignant melanoma metastatic to the vitreous. *Arch Ophthalmol* 1986;104:98-101.
54. Meisler DM, Palestine AG, Vastine DW, Demartini DR, Murphy BF, Reinhart W, Zakov ZN, McMahon JT, Cliffl T. Propionibacterium endophthalmitis after extracapsular cataract extraction and intraocular lens implantation. *Am J Ophthalmol* 1986;102:733-739.
55. Meisler DM, Zakov ZN, Bruner WE, Hall GS, McMahon JT, Zachary AA, Barna BP. Endophthalmitis associated with sequestered intraocular Propionibacterium acnes. *Am J Ophthalmol* 1987;104:428-429.
56. Berlin LA, Zakov ZN. Ultrasonographic evaluation of hemorrhagic choroidal detachments. In Ossoinig C (ed). *Ophthalmic Echography, Documenta*

- Ophthalmologica Proceedings Series 48*. Dordrecht: M. Nijhoff/W. Junk Publishers, 1987, pp. 313-318.
57. McAllister IL, Meyers SL, Zegarra H, Gutman FA, Zakov ZN, Beck GJ. Comparison of pneumatic retinopexy with alternative surgical techniques. *Ophthalmology* 1988;95:877-883.
 58. Kincaid MC, Folberg R, Torczynski E, Zakov ZN, Shore JW, Liu SJ, Planchard T, Weingeist TA. Complications after proton beam therapy for uveal malignant melanoma. *Ophthalmology* 1988;95:982-991.
 59. Straatsma BR, Fine SL, Earle JD, Hawkins BS, Diener-West M, McLaughlin JA, Collaborative Ocular Melanoma Study Research Group. Enucleation versus plaque irradiation for choroidal melanoma. *Ophthalmology* 1988;95:1000-1004.
 60. Gardner TW, Norris JL, Zakov ZN, Williams GW. A survey of intraocular gas use in North America. *Arch Ophthalmol* 1988;106:1188-1189.
 61. Romania A, Zakov ZN, McGannon E, Schroeder T, Heyen F, Jagelman DG. Congenital hypertrophy of the retinal pigment epithelium in familial adenomatous polyposis. *Ophthalmology* 1989;96:879-884.
 62. Collaborative Ocular Melanoma Study Steering Committee. Failure of pre-enucleation radiation to decrease uveal melanoma mortality. *Am J Ophthalmol* 1989;107:440-441.
 63. Ambler JS, Meisler DM, Zakov ZN, Hall GS, Spech TJ. Endogenous Mycobacterium chelonae endophthalmitis. *Am J Ophthalmol* 1989;108:338-339.
 64. Perkovich BT, Zakov ZN, Berlin LA, Weidenthal D, Avins LR. An update on multiple recurrent serosanguineous retinal pigment epithelial detachments in black women. *Retina* 1990;10:18-26.
 65. Varley GA, Meisler DM, Benes SC, McMahan JT, Zakov ZN, Fryczkowski AF. Hibiclens keratopathy. A clinicopathologic case report. *Cornea* 1990;9:341-346.
 66. Schachat AP, Markowitz JA, Hawkins BS, Fine SL, Collaborative Ocular Melanoma Study Group. Nonocular cancers in patients with choroidal melanoma. [Letter] *Ophthalmology* 1990;97:837-838.
 67. Collaborative Ocular Melanoma Study Group. Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS Report No. 1. *Arch Ophthalmol* 1990;108:1268-1273.
 68. Marcus DM, Minkovitz JB, Wardwell SD, Albert DM for the Collaborative Ocular Melanoma Study Group. The value of nucleolar organizer regions in uveal melanoma. *Am J Ophthalmol* 1990;110:527-534.
 69. Zakov ZN. Managing diabetic retinopathy. *Cleve Clin J Med* 1990;57:609-612.

70. Heyen F, Jagelman DG, Romania A, Zakov ZN, Lavery IC, Fazio VW, McGannon E. Predictive value of congenital hypertrophy of the retinal pigment epithelium as a clinical marker for familial adenomatous polyposis. *Dis Colon Rectum* 1990;33:1003-1008.
71. Romania A, Zakov ZN, Church JM, Jagelman DG. Retinal pigment epithelium lesions as a biomarker of disease in patients with familial adenomatous polyposis. A follow-up report. *Ophthalmology* 1992;99:911-913.
72. Foster RE, Lowder CY, Meisler DM, Zakov ZN. Extracapsular cataract extraction and posterior chamber intraocular lens implantation in uveitis patients. *Ophthalmology* 1992;99:1234-1241.
73. Lowder CY, Foster RE, Meisler DM, Zakov ZN. Combined extracapsular cataract extraction, posterior chamber intraocular lens implantation, and pars plana vitrectomy. *Ophthalmic Surg* 1993;24:446-452.
74. Zakov ZN. Endoftalmilerde ve travmalarda vitrektomi. *Retina-Vitreus*, Cilt 1, Sayı 2, Aralık 1993, p. 122.
75. Collaborative Ocular Melanoma Study Group. Complications of enucleation surgery. COMS Report No. 2. In Franklin RM (ed). *Proceedings of the Symposium on Retina and Vitreous, New Orleans Academy of Ophthalmology*. New York: Kugler Publications, 1993, pp 181-190.
76. Collaborative Ocular Melanoma Study Group. Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study. COMS Report No. 3. *Controlled Clin Trials* 1993;14:362-391.
77. Kalenak JW, Zakov ZN. Presumed sudden leakage of a pilocarpine ocusert and rhegmatogenous retinal detachment. *J Glaucoma* 1994;3:152-153.
78. Schachat AP for the Collaborative Ocular Melanoma Study Group. Management of uveal melanoma: a continuing dilemma. [Letter] *Cancer* 1994;74:3073-3075.
79. Carroll BF, Peyman GA, Mehta NJ, Millsap CM, Greve MD, Dunlap WA, Lee KJ, Ma PE for the Vitreous Study Group. Repair of retinal detachment associated with proliferative vitreoretinopathy using perfluoroperhydrophenanthrene (Vitreon). *Can J Ophthalmol* 1994;29:66-69.
80. Zegarra H, Zakov ZN, Lamkin JC, Addiego R, Singerman LJ. Laser therapy for retinal vein occlusions. In Karlin DB (ed). *Lasers in Ophthalmology*. Cambridge, Mass: Blackwell Scientific Publications, Inc, p.140, 1995.
81. Verma LK, Peyman GA, Wafapoor H, Greve MD, Millsap CM, Adile SL. An analysis of posterior segment complications after vitrectomy using the

- perfluorocarbon perfluoroperhydrophenanthrene (Vitreon). Vitreon Collaborative Study. *Ophthalmic Surg* 1995;26:29-33.
82. Chern KC, Meisler DM, Hall GS, Meyers SM, Foster RE, Zakov ZN, Lowder CY. Bacterial contamination of anaerobic vitreous cultures: using techniques employed for endophthalmitis. *Curr Eye Res* 1996;15:697-699.
 83. Wells CG, Bradford RH, Fish GE, Straatsma BR, Hawkins BS for the COMS Group. Choroidal melanomas in American Indians. *Arch Ophthalmol* 1996;114:1017-1018.
 84. Soheilian M, Peyman GA, Wafapoor H, Navarro GC, Thompson H, the Vitreon Study Group. Surgical management of traumatic retinal detachment with perfluorocarbon liquid. *Int Ophthalmol* 1996-1997;20:241-249.
 85. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. *Arch Ophthalmol* 1997;115:865-872.
 86. The Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma. COMS Report No. 4. *Arch Ophthalmol* 1997;115:886-893.
 87. The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma. COMS Report No. 5. *Arch Ophthalmol* 1997;115:1537-1544.
 88. Grossniklaus HE, Albert DM, Green WR, Conway BP, Hovland KR for the Collaborative Ocular Melanoma Study Group. Clear cell differentiation in choroidal melanoma. COMS report no. 8. *Arch Ophthalmol* 1997;115:894-898.
 89. Kertes PJ, Wafapoor H, Peyman GA, Calixto Jr N, Thompson H, Vitreon Collaborative Study Group. The management of giant retinal tears using perfluoroperhydrophenanthrene. *Ophthalmology* 1997;104:1159-1165.
 90. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. *Arch Ophthalmol* 1997;115:865-872.
 91. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in eyes with large drusen. Short-term effects seen in a pilot randomized clinical trial. *Ophthalmology* 1998;105:11-23.
 92. Parnes RE, Zakov ZN, Novak MA, Rice TA. Vitrectomy in patients with decreased visual acuity secondary to asteroid hyalosis. *Am J Ophthalmol* 1998;125:703-704.

93. The Collaborative Ocular Melanoma Study Group. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS Report No. 6. *Am J Ophthalmol* 1998;125:745-766.
94. The Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. I. Characteristics of patients enrolled and not enrolled. COMS Report No. 9. *Am J Ophthalmol* 1998;125:767-778.
95. The Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma. II. Initial mortality findings. COMS Report No. 10. *Am J Ophthalmol* 1998;125:779-796.
96. Collaborative Ocular Melanoma Study Group: The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma III. Local complications and observations following enucleation. COMS Report No. 11. *Am J Ophthalmol* 1998;126: 362-372.
97. Tomsak R, Zakov ZN. Nonarteritic anterior ischemic optic neuropathy with macular edema: visual improvement and fluorescein angiographic characteristics. *J Neuro-Ophthalmol* 1998;18:166-168.
98. Choroidal Neovascularization Prevention Trial Research Group. Choroidal neovascularization in the choroidal neovascularization prevention trial. *Ophthalmology* 1998;105:1364-1372.
99. Pendergast SD, Zakov ZN, Novak MA. Lasers in vitreous surgery. In Singerman LJ, Coscas G (eds). *Current Techniques in Ophthalmic Laser Surgery*. Philadelphia: Current Medicine, pp 153-164, 1999.
100. Cruickshanks KJ, Fryback DG, Nondahl DM, Robinson N, Keesey U, Dalton DS, Robertson DM, Chandra SR, Mieler WF, Zakov ZN, Custer PL, Del Priore LV, Albert DM. Treatment choice and quality of life in patients with choroidal melanoma. *Arch Ophthalmol* 1999;117:461-467.
101. Collaborative Ocular Melanoma Study Group. Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study. COMS Report No. 12. *J Ophth Nurs Technol* 1999;Part I 18:143-149, Part II 18:219-232.
102. Meffert S, Peyman GA, the Vitreous Study Group. Intraoperative complications of perfluoroperhydrophenanthrene: subretinal perfluorocarbon, retinal slippage and residual perfluorocarbon. *Can J Ophthalmol* 1999;34:272-280.
103. Purohit SS, Matthews GP, Zakov ZN. Pneumatic buckle for the repair of primary rhegmatogenous retinal detachment. *Ophthalmic Lasers and Surgery* 1999;30:509-512.

104. COMS Quality of Life Study Group. Quality of life assessment in the collaborative ocular melanoma study: design and methods. COMS-QOLS Report No. 1. *Ophthalmic Epidemiol* 1999;6:5-17.
105. Choroidal Neovascularization Prevention Trial Research Group. Laser-induced drusen reduction improves visual function at 1 year. *Ophthalmology* 1999;106:1367-1373.
106. Scott IU, Moy CS, Murray TG for the COMS Group. Update on the Collaborative Ocular Melanoma Study (COMS) for the comprehensive ophthalmologist. *Comp Ophthalmol Update* 2000;1:185-191.
107. Moy CS, Albert DM, Diener-West M, McCaffrey LD, Scully RE, Willson JK; The Collaborative Ocular Melanoma Study Group, prepared by COMS Mortality Coding Committee. Cause-specific mortality coding. Methods in the Collaborative Ocular Melanoma Study. COMS Report No. 14. *Control Clin Trials* 2001;22:248-262.
108. The Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS Report No. 15. *Arch Ophthalmol* 2001;119:670-676.
109. The Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years. COMS Report No. 16. *Ophthalmology* 2001;108:348-366.
110. Grostern RJ, Slusker Shternfeld I, Bacus SS, Gilchrist K, Zimbric ML, Albert DM; Collaborative Ocular Melanoma Study Group. Absence of type I estrogen receptors in choroidal melanoma: analysis of Collaborative Ocular Melanoma Study (COMS) eyes. *Am J Ophthalmol* 2001;131:788-791.
111. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for choroidal melanoma, II: Characteristics of patients enrolled and not enrolled. COMS Report No. 17. *Arch Ophthalmol* 2001;119:951-965.
112. Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for choroidal melanoma, III. Initial mortality findings. COMS Report No. 18. *Arch Ophthalmol* 2001;119:969-982.
113. Zakov ZN. Foreword, in Kuhn F, Pieramici DJ (eds.), *Ocular Trauma: Principles and Practice*. Thieme: New York, 2002, pp xiii-xiv.
114. Collaborative Ocular Melanoma Study Group. Sociodemographic and clinical predictors of participation in two randomized trials: Findings from the Collaborative Ocular Melanoma Study. COMS Report No. 7. *Controlled Clin Trials* 2001;22:526-537.

115. Byrne SF, Marsh MJ, Boldt HC, Green RL, Johnson RN, Wilson DJ. Consistency of observations from echograms made centrally in the Collaborative Ocular Melanoma Study COMS Report No. 13. *Ophthalmic Epidemiol* 2002;9:11-27.
116. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. *Retina* 2002;22:143-152.
117. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Three-year results of an open-label extension of 2 randomized clinical trials – TAP report No. 5. *Arch Ophthalmol* 2002;120:1307-1314.
118. Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS Report No. 19. *Ophthalmology* 2002;109:2197-2206. (Correction: *Ophthalmology* 2004; 111:1514)
119. Diener-West M, Hawkins B, the Collaborative Ocular Melanoma Study Group. Changing current practice. Implementing large multicenter trials for a rare condition. *Applied Clinical Trials* 2002;11(9):48-54.
120. Hollick RA, Reynolds SM, the Collaborative Ocular Melanoma Study Group. Adding centers to boost subject accrual: a case study for a rare condition. *Applied Clinical Trials* 2002;11 (10):54-59.
121. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. *Retina* 2002;22:143-52.
122. Scott IU, Murray TG, Flynn HW Jr, Feuer WJ, Schiffman JC, Perfluoron Study Group. Outcomes and complications associated with giant retinal tear management using perfluoro-n-octane. *Ophthalmology* 2002;109:1828-1833.
123. Straatsma BR, Diener-West M, Caldwell R, Engstrom RE, Collaborative Ocular Melanoma Study Group. Mortality after deferral of treatment or no treatment for choroidal melanoma. *Am J Ophthalmol* 2003;136:47-54.
124. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Zilliox P, The Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. *Retina* 2003;23:14-23.

125. Choroidal Neovascularization Prevention Trial Research Group. Laser treatment in fellow eyes with large drusen: updated findings from a pilot randomized clinical trial. *Ophthalmology* 2003;110:971-978.
126. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. *Ophthalmology* 2003;110:2372-2383.
127. Melia M, Moy CS, Reynolds SM, Cella D, Murray TG, Hovland KR, Hayman JA, Mangione CM, The Collaborative Ocular Melanoma Study-Quality Of Life Study Group. Development and validation of disease-specific measures for choroidal melanoma: COMS-QOLS report No. 2. *Arch Ophthalmol* 2003;121:1010-1020.
128. Collaborative Ocular Melanoma Study Group. Trends in size and treatment of recently diagnosed choroidal melanoma, 1987-1997: findings from patients examined at collaborative ocular melanoma study (COMS) centers: COMS Report No. 20. *Arch Ophthalmol* 2003;121:1156-1162.
129. Collaborative Ocular Melanoma Study Group. Comparison of clinical, echographic, and histopathological measurements from eyes with medium-sized choroidal melanoma in the collaborative ocular melanoma study: COMS Report No. 21. *Arch Ophthalmol* 2003;121:1163-1171.
130. Azab M, Benchaboune M, Blinder KJ, et al; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group; Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. *Retina* 2004;24:1-12.
131. Gurelik G, Coney JM, Zakov ZN. Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study. *Ophthalmic Surg Lasers Imaging* 2004;35:94-102.
132. Collaborative Ocular Melanoma Study Group. Ten-year follow-up of fellow eyes of patients enrolled in Collaborative Ocular Melanoma Study (COMS) randomized trials. COMS Report No. 22. *Ophthalmology* 2004;111:966-976.
133. Complications of Age-related Macular Degeneration Prevention Trial Study Group. The Complications of Age-related Macular Degeneration Prevention Trial (CAPT): rationale, design, and methodology. *Clinical Trials* 2004;1:91-107.
134. Mobley RY, Moy CS, Reynolds SM, Diener-West M, Newhouse MM, Kerman JS, Hawkins BS; Collaborative Ocular Melanoma Study Group. Time trends in personnel

- certification and turnover in the Collaborative Ocular Melanoma Study. *Clin Trials* 2004;1:377-386.
135. Maguire M; Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Baseline characteristics, the 25-Item National Eye Institute Visual Functioning Questionnaire, and their associations in the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT). *Ophthalmology* 2004;111:1307-1316.
 136. Hawkins BS, Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. *Am J Ophthalmol* 2004;138:936-951.
 137. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med* 2004;351:2805-2816.
 138. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Straatsma BR, Thoma J; Collaborative Ocular Melanoma Study Group. Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma: COMS Report No. 25. *Arch Ophthalmol* 2005;123:601-604.
 139. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Straatsma BR, Thoma J; Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. *Arch Ophthalmol* 2005;123:1639-1643.
 140. Melia M, Moy CS, Reynolds SM, Hayman JA, Murray TG, Hovland KR, Earle JD, Kurinij N, Dong LM, Miskala PH, Fountain C, Cella D, Mangione CM; Collaborative Ocular Melanoma Study-Quality of Life Study Group. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. *Arch Ophthalmol* 2006;124:226-238.
 141. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. *Arch Ophthalmol* 2006;124:1684-1693.
 142. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. *N Engl J Med* 2006;355:1432-1444.

143. Complications of Age-Related Macular Degeneration Prevention Trial Research Group. Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. *Ophthalmology* 2006; 113:1974-1986.
144. Russell SR, Hudson HL, Jerdan JA; Anecortave Acetate Clinical Study Group. Anecortave acetate for the treatment of exudative age-related macular degeneration--a review of clinical outcomes. *Surv Ophthalmol* 2007;52 Suppl 1:S79-90.
145. Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreal dexamethasone drug delivery system in patients with persistent macular edema. *Arch Ophthalmol* 2007;125:309-317.
146. Collaborative Ocular Melanoma Study Group. Incidence of cataract and outcomes after cataract surgery in the first 5 years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study: COMS Report No. 27. *Ophthalmology* 2007;114:1363-1371. Epub 2007 Mar 6.
147. Macugen AMD Study Group, Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. *Ophthalmology* 2007;114:1702-1712.
148. Qian Y, Zakov ZN, Schoenfield L, Singh AD. Iris melanoma arising in iris nevus in oculodermal melanocytosis. *Surv Ophthalmol* 2008;53:411-415.
149. Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa M, Harrington MW; Macular Telangiectasia Research Group. The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project. *Invest Ophthalmol Vis Sci* 2008;49:4340-4346.
150. Collaborative Ocular Melanoma Study Group, Boldt HC, Byrne SF, Gilson MM, Finger PT, Green RL, Straatsma BR, Simpson ER, Hawkins BS. Baseline echographic characteristics of tumors in eyes of patients enrolled in the Collaborative Ocular Melanoma Study: COMS report no. 29. *Ophthalmology* 2008;115:1390-1397. Epub 2008 Feb 11.
151. Boldt HC, Melia BM, Liu JC, Reynolds SM; Collaborative Ocular Melanoma Study Group. I-125 brachytherapy for choroidal melanoma photographic and angiographic abnormalities: the Collaborative Ocular Melanoma Study: COMS Report No. 30. *Ophthalmology* 2009;116:106-115.
152. Elman M and the SCORE Study Investigator Group. SCORE Study Report 3: Study design and baseline characteristics. *Ophthalmology* 2009;116:1770-1777.

153. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. *Arch Ophthalmol* 2009;127:1101-1114.
154. The SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. *Arch Ophthalmol* 2009;127:1115-1128.
155. Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA, Antoszyk AN; SCORE Study Investigator Group. SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe design. *Am J Ophthalmol* 2009;148:725-732.
156. Hood CT, Budd GT, Zakov ZN, Singh AD. Male breast carcinoma metastatic to the choroid: report of 3 cases and review of the literature. *Eur J Ophthalmol*. 2010 Dec 22. pii: CE9E4FC5-B4E3-4F12-84C8-A8E72C69C039. [Epub ahead of print]
157. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; Ozurdex Geneva Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. *Ophthalmology* 2010;117:1134-1146.
158. Chan CK, Ip MS, Vanveldhuisen PC, Oden NL, Scott IU, Tolentino MJ, Blodi BA; SCORE Study Investigator Group. SCORE Study Report #11. Incidences of neovascular events in eyes with retinal vein occlusion. *Ophthalmology* 2011;118:1364-1372.
159. Sallo FB, Leung I, Chung M, Wolf-Schnurrbusch UE, Dubra A, Williams DR, Clemons T, Pauleikhoff D, Bird AC, Peto T; MacTel Study Group. Retinal crystals in type 2 idiopathic macular telangiectasia. *Ophthalmology* 2011;118:2461-2467.
160. Coney JM, Zegarra H, Zakov ZN. Treatment of serous retinal detachments in optic nerve head pits with periocular steroids and carbonic anhydrase inhibitors: case studies (*in preparation*).
161. Coney JM, Zegarra H, Zakov ZN. The efficacy of binocular indirect laser in the treatment of ischemic central retinal vein occlusions (*in preparation*).
162. Coney JM, Zegarra H, Zakov ZN. Prophylactic binocular indirect laser for the prevention of recurrent retinal detachments in scleral buckle removal (*in preparation*).

Abstracts

1. Zakov ZN, Gragoudas ES, Albert DM, Constable IJ. Long-term observation in proton-irradiated monkey eyes. *Invest Ophthalmol Vis Sci* (suppl), April 1979, p. 45.
2. Ricker DP, Zakov ZN, Albert DM, Craft JL, Klepach GL, Keltner JL. Studies of the pathogenesis and morphology of temporal arteritis. *Invest Ophthalmol Vis Sci* (suppl), April 1979, p. 205.
3. Fulton AB, Craft JL, Zakov ZN. Retinal anomalies in Trisomy 18. *Invest Ophthalmol Vis Sci* (suppl), April 1979, p. 44.
4. Zegarra H, Gutman FA, Zakov ZN, Carim M. Partial central retinal vein occlusion. *Invest Ophthalmol Vis Sci* (suppl), March 1981, p. 142.
5. Albanese U, Zakov ZN, Zegarra H. Xenon endophotocoagulation and neovascular glaucoma in postvitrectomy diabetic eyes. *Invest Ophthalmol Vis Sci* (suppl), March 1983, p. 58.
6. Zakov ZN, Tubbs RR, Lamping A., Albert DM, Robinson N. Immunohistochemical findings in giant cell arteritis. *Invest Ophthalmol Vis Sci* (suppl): 246, 1983.
7. Fitzgibbon EJ, Price RL, Zegarra H, Zakov ZN. Complications after lensectomy surgery for congenital cataract. *Invest Ophthalmol Vis Sci* 25 (suppl):172, 1983.
8. Rosenfeld SI, Culbertson WW, Meisler DM, Zakov ZN, Cliffler TP, Rabon R, Langston RHS. Phacoanaphylactic uveitis following extracapsular cataract extraction with posterior chamber lens implant. *Ophthalmology* 92:60S, 1985.
9. Cole EL, Zakov ZN, Hack BG, Meisler DM, Zegarra H, Berlin AJ, Berlin LA, Ellsworth RH, Chang S. The varied representation of cutaneous malignant melanoma metastatic of the eye and orbit. *Ophthalmology* 92:101S, 1985.
10. Fine SL, Straatsma BR, Hawkins BS, Schachat AP, Collaborative Ocular Melanoma Study Group. Collaborative Ocular Melanoma Study. *Invest Ophthalmol Vis Sci* 27 (3, suppl):312, 1986.
11. COMS Group. The Collaborative Ocular Melanoma Study. *Ophthalmology* 93 (suppl):135, 1986.
12. Meisler DM, Zachary AA, Braun WE, Barna BP, Hall GS, Zakov ZN. Association of DQW1 with uveitis following cataract extraction. *Invest Ophthalmol Vis Sci* 28: (suppl): 43, 1987.
13. Diener-West M, Hawkins BS, Fine SL for the COMS Research Group. Challenges in designing and conducting a clinical trial for a rare condition. *Invest Ophthalmol Vis Sci* 28: (suppl): 393, 1987.

14. Markowitz JA, Hawkins BS, Diener-West M, Schachat AP, Fine SL, Straatsma BR, Earl JD, Collaborative Ocular Melanoma Study Group. Baseline characteristics of the first 450 cases evaluated for the Collaborative Ocular Melanoma Study. *Invest Ophthalmol Vis Sci* 29 (suppl):120, 1988.
15. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study. *Ophthalmology* 95 (suppl):190, 1988.
16. Heyen F, Jagelman DG, Lavery IC, Fazio VW, Romania A, Zakov ZN, McGannon E. The predictive value of congenital hypertrophy of the retinal pigment epithelium as a clinical marker for familial adenomatous polyposis. *ASCRS Annual Convention*, 1989.
17. Meyers S, Lowder CY, Meisler DM, Zakov ZN. Vitrectomy in young uveitis patients. *Invest Ophthalmol Vis Sci* 31 (suppl):141, 1990.
18. Markowitz JA, Willis DM, Collaborative Ocular Melanoma Study Research Group. Is standardization possible in a multicenter clinical trial in which 45 medical centers and 500 clinical professionals are involved? *Controlled Clin Trials* 11:289, 1990.
19. Diener-West M, Willis DM, Hawkins BS for the Collaborative Ocular Melanoma Study Group. Sociodemographic factors of patient participation in randomized trials. Findings from the COMS. *Invest Ophthalmol Vis Sci* 32 (4, suppl):980, 1991.
20. Hawkins BS, Fine SL, Straatsma BR, Mowery RL, Earle JD for the COMS Group. Five-year progress report from the Collaborative Ocular Melanoma Study. *Invest Ophthalmol Vis Sci* 33 (4, suppl):1254, 1992.
21. Kirkwood JM, Earle JD, Fine SL, Hawkins BS, Straatsma BR, Mowery RL for the COMS Group. Five-year progress report: The Collaborative Ocular Melanoma Study. *Proc ASCO* 11:349, 1992.
22. Collaborative Ocular Melanoma Study Group. Five-year progress report from the Collaborative Ocular Melanoma Study. *Ophthalmology* 99 (suppl):158, 1992.
23. Moy CS for the COMS Group. Factors predictive of choice of treatment among patients with choroidal melanoma. *Invest Ophthalmol Vis Sci* 34:967, 1993.
24. Coates TC for the COMS Coordinating Center: Archiving and material storage for a long-term clinical trial. *Controlled Clin Trials* 14:448, 1993.
25. Manos KS, Moy CS for the COMS Group. Phantom or real? Verification of nonrandomized patients evaluated for randomized clinical trials of a rare disease. *Controlled Clin Trials* 14:441, 1993.
26. Montague PR, Melia M, Weingeist TA, COMS Group. Evaluation of radiation retinopathy with color photography alone vs color photography with fluorescein angiography. *Invest Ophthalmol Vis Sci* 35:1722, 1994.

27. Albert DM, Green WR, Grossniklaus HE, Diener-West M for the Collaborative Ocular Melanoma Study Group. Histopathologic review of 1,091 uveal melanomas. *Invest Ophthalmol Vis Sci* 35:1925, 1994.
28. Umlas J, Albert D, Diener-West M, for the Collaborative Ocular Melanoma Study Group. Correlation of transillumination size and microscopic measurement of choroidal melanoma. *Invest Ophthalmol Vis Sci* 35:1925, 1994.
29. Coates TC, Hawkins BS, for the COMS Group. (Un)Predictability of accrual in randomized clinical trials. *Controlled Clin Trials* 16 (suppl): 83, 1995.
30. Romania A, Zakov ZN, Church JM, Jagelman DG, Heyen F, McGannon EA. Three-year follow-up of patients with familial adenomatous polyposis. *Ophthalmology* 101:171S, 1994.
31. Chern KC, Meisler DM, Hall GS, Meyers SM, Foster RE, Lowder CY, Zakov ZN. Bacterial contamination of vitreous cultures using techniques employed for endophthalmitis. *Invest Ophthalmol Vis Sci* 36 (suppl):790, 1995.
32. Melia BM, Diener-West M, Folk JC, Bennett SR, Montague PR, Weingeist TA, for the COMS Group. Mortality and tumor growth in patients with choroidal melanoma: a report from the COMS Group. *Invest Ophthalmol Vis Sci* 36 (4, suppl):1036, 1995.
33. Manos KS, Hollick RA for the COMS Group. Does workspace affect coordinator performance in a randomized clinical trial? *Controlled Clin Trials* 17 (2, suppl):134, 1996.
34. Manos KS, Moy CS for the COMS-QOLS Group. Incorporating a quality of life assessment into an ongoing multi-center clinical trial: problems and recommendations. *Controlled Clin Trials* 18(3, suppl):104, 1997.
35. Earle JD, Schachat AP, Fine SL, Hawkins BS, Diener-West M for the COMS. Three-year results of enucleation surgery with or without preoperative radiation therapy (PERT) in the prospective randomized Collaborative Ocular Melanoma Study (COMS) large tumor trial. *Int J Rad Oncol Biol Phys* 39(2, Suppl): 159, 1997.
36. Moy CS, Melia BM, Gutierrez PR, Mangione CM for the COMS-QOLS Group. Validity of the Visual Functioning Questionnaire in patients with choroidal melanoma: a pilot study. *Quality of Life Res* 6:693, 1997.
37. Moy CS, Melia BM, Gutierrez PR, Mangione CM for the COMS-QOLS Group: Assessment of visual functioning with the NEI-VFQ in patients with choroidal melanoma: a pilot study. *Invest Ophth Vis Sci* 38:S841, 1997.
38. Matthews GP, Purohit SS, Zakov ZN. Repair of primary rhegmatogenous retinal detachment by pneumatic buckle *Invest Ophthalmol Vis Sci* 39 (4, suppl):207 (abstract #969), 1998.

39. Zakov ZN. Intraocular lens compatibility with vitreous substitutes. *XXVIIIth International Congress of Ophthalmology*. Amsterdam, p. 55, 1998.
40. Imesch PD, Levitt BT, Albert DM for the COMS Group: Apoptosis in intraocular and metastatic melanomas. *Invest Ophthalmol Vis Sci* 39(4,suppl):414, 1998.
41. Hollick RA, Reynolds SM for the COMS Group: The impact of adding new clinical centers during the course of a clinical trial for a rare condition. *Controlled Clin Trials* 19(3, suppl):69, 1998.
42. Maguire MG, Fine SL, Maguire AM, D'Amato RJ, Singerman LJ, the AMDATS Research Group. Results of the Age-related Macular Degeneration and Thalidomide Study (AMDATS). *ARVO Abstracts*, #1255, 2001.
43. Coney JM, Gurelik G, Zakov NZ. Binocular indirect panretinal laser photocoagulation for the treatment of proliferative diabetic retinopathy: a retrospective study. *ARVO Abstracts* 2003; Program # 3982; Poster# B685; <http://www.abstractsonline.com/viewer/viewAbstract.asp?CKey={1E66400E-DDCC-49B7-9CF4-C0676D3FFE03}&MKey={B7EE4F95-9F5C-4CE7-BE3E-4546DC966490}&AKey={01DBD563-E053-4A16-A83F-48E737512973}&SKey={BCB65E99-6D51-460B-9BB8-8A0B2CE41CE8}>, accessed May 2003.

National Technical Information Service

1. Collaborative Ocular Melanoma Study Group. COMS Study Forms Book, PB91-217315, National Technical Information Service, Springfield, Virginia, May 1991.
2. Collaborative Ocular Melanoma Study Group. COMS Manual of Procedures. PB95-179693, National Technical Information Service, Springfield, Virginia, January 1995.

Book Reviews

1. *Handbook of Ophthalmology*. Authors: Thomas W. Gardner and David E. Shoch. *Cleve Clin J Med* 55:569, 1988.
2. *Stereoscopic Atlas of Macular Disease. Diagnosis and Treatment*. Author: J. Donald M. Gass. *Cleve Clin J Med* 55:571, 1988.
3. *Diabetes and Its Ocular Complications*. Authors: William E. Benson, Gary C. Brown, and William Tasman. *Cleve Clin J Med* 57:100, 1990.
4. *New Microsurgical Concepts II, Vol. 18*. Editors: J. Draeger and R. Winter. *Ocular Surgery News*, March 1, 1990.
5. *Proliferative Vitreoretinopathy*. Editors: K. Heiman and P. Wiedemann. *Ocular Surgery News*, April 15, 1990.

6. *Retina*. Editor-in-Chief: Steven J. Ryan. Cleve Clin J Med 57:492, 1990.
7. *Retinal Pigment Epithelium*. Editors: M. Zingirian and F. Cardillo Piccolino. Ocular Surgery News, January 15, 1991.
8. *Ophthalmic Lasers*. Author: Francis A. L'Esperance, Jr. Cleve Clin J Med, March-April, 1991.
9. *Retinal and Choroidal Manifestations of Systemic Diseases*. Editors: L. Singerman and L. Jampol. Ocular Surgery News, July 15, 1991.
10. *Laser Surgery of the Posterior Segment*. Authors: Steven M. Bloom and Alexander J. Brucker. Ocular Surgery News, August 15, 1991.
11. *Eye Trauma*. Editors: BJ Shingleton, PS Hersh, and KR Kenyon. Ocular Surgery News, March 15, 1992.
12. *Fluorescein Angiography*. Authors: Joseph W. Berkow, David H. Orth, and James S. Kelly. Ocular Surgery News, November 15, 1992.
13. *Practical Atlas of Retinal Disease and Therapy*. Editor: William R. Freeman. Ocular Surgery News, May 1, 1993.

June 2011